UCLA researchers advance EGFR-targeted drug for glioblastoma into clinical testing

Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation. Researchers at UCLA are advancing a glioblastoma drug candidate designed specifically for the biology and anatomy of brain tumors. Early clinical testing showing signs that the therapy can reach the brain at potentially meaningful levels. The drug, KTM-101, was developed to target alterations in epidermal growth factor receptor, or EGFR, a molecular driver found in more than half of glioblastomas. The investigational therapy is designed to cross the blood-brain barrier. From there, it selectively targets EGFR mutations associated with glioblastoma, according to UCLA…

Source: Drug Discovery & Development